Advertisement

Topics

Benefit-to-risk ratio of GBCAs remains 'extremely high'—but evaluation should be done for each exam

13:17 EDT 16 Apr 2018 | Cardiovascular Business

Benefit-to-risk ratio of GBCAs remains 'extremely high'—but evaluation should be done for each exam mrohman Mon, 04/16/2018 - 17:17

Original Article: Benefit-to-risk ratio of GBCAs remains 'extremely high'—but evaluation should be done for each exam

NEXT ARTICLE

More From BioPortfolio on "Benefit-to-risk ratio of GBCAs remains 'extremely high'—but evaluation should be done for each exam"

Advertisement
Quick Search
Advertisement
Advertisement